4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Eupraxia Pharmaceuticals Inc. (EPRX) operates in the Biotechnology industry and is headquartered in Victoria, Canada with about 49 employees. Its market capitalization is roughly $447 million. In the fiscal year ended 2025-12-31, EPRX reported $0M in revenue and ($39M) in net income.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($38M) | ($27M) | ($28M) | ($18M) | — |
| Net Income | ($39M) | ($26M) | ($28M) | ($18M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($16M) | ($16M) | ($7M) | ($8M) | ($7M) | — |
| Net Income | ($13M) | ($17M) | ($6M) | ($9M) | ($7M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $86M | $35M | $20M | $19M | — |
| Total Liabilities | $6M | $3M | $19M | $12M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EPRX viewer.
About TickerBase · Data methodology & sources